Back to top

gene-therapy: Archive

Sundeep Ganoria

CRISPR (CRSP) Loses 24% YTD: How Should You Play the Stock?

Despite gaining regulatory approvals in many countries for the first ever CRISPR-based gene therapy, investors should remain wary of investing in CRISPR Therapeutics' (CRSP) early-stage pipeline.

VRTXPositive Net Change BEAMNegative Net Change EDITNegative Net Change CRSPNegative Net Change

Zacks Equity Research

Sarepta (SRPT) Q2 Earnings Top Estimates, Sales Lag, View Weak

Sarepta (SRPT) reports mixed results in the second quarter. It issues revenue guidance for 2025, which is below expectations. Stock falls during after-market trading.

RHHBYNegative Net Change SRPTNegative Net Change IMTXNegative Net Change TRDAPositive Net Change

Ekta Bagri

Prime Medicine (PRME) Stock: Buy or Sell Before Q2 Earnings?

While Prime Medicine's (PRME) pipeline progress is encouraging, the precarious cash position is worrisome. We advise a wait-and-watch approach before Q2 results.

VRTXPositive Net Change PRMENegative Net Change CRSPNegative Net Change